Ebenbuild
Munich
About Ebenbuild
Based on two decades of trailblazing fundamental research at TU Munich, Germany, Ebenbuild develops and commercializes a deep tech/health tech platform technology to provide pinpoint health intelligence for respiratory diseases. Based on lung simulation models, the technological versatility allows for a broad spectrum of applications in health care and life sciences, currently with two initial applications. Our digital trials application de-risks and accelerates drug development by predicting the success of drug delivery to the lung in individuals and cohorts. Being of essential value to Biotech, Pharma, and MedTech companies, the application allows for the in silico optimization of all relevant delivery parameter before going into the decisive clinical phases, increasing speed and boosting chances of success. The data-based knowledge will be used in companion diagnostics post-clearance. Our health care application integrates that product into hospital IT and is on its path to regulatory clearance. It delivers precise actionable intelligence to the patient bedside, starting with the personalization of mechanical ventilation of patients with Acute Respiratory Distress Syndrome (ARDS), a complication in millions of patients each year. Personalized ventilation means a much better short-term and long-term prognosis, which benefits patients, medical staff, hospitals and payors. Adding indication by indication, the platform grows.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $2.7M
- Funding stage: Seed
- Last round: Grant (Jul 2025)
- Website: ebenbuild.com
- Phone: +49 (0)89 215 254 77
Industries & Categories
Health Care, Medical Device, Software
Social Profiles
Canonical: https://fsome.com/organization/ebenbuild-17540 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.